Wall Street 24/7
By Chris Lange July 21, 2015 5:29 pm EDT
Exelixis announced positive top-line results from its primary analysis of METEOR, the Phase 3 pivotal trial comparing cabozantinib to everolimus in 658 patients with metastatic renal cell carcinoma (RCC). These patients have experienced disease progression following treatment with a VEGF receptor tyrosine kinaseinhibitor. Cabozantinib reduced the risk of disease progression or death by 42% compared to the everolimus
Vantage Point Trading
Trading Stock Picks for the Week of July 27 ( ZIOP )
Netflix global expansion just starting
Cramer -- Investors Dislike Horizon Pharma Bid but Can Push Fitbit Higher
By Bret Kenwell
Turning to Fitbit (FIT), Cramer said analysts at Baird initiated the stock with an outperform rating and $52 price target. Cramer said that, if anything, the analysts were too conservative in their margin estimate because consumers are buying the company's products "hand over fist."
According to the analysts' survey, Fitbit is in higher demand than the Apple (AAPL) Watch. A short squeeze could push the stock even higher, he concluded.
thanks for the shares
US IPO Weekly Recap: 8 companies go public
Renaissance Capital, June 23, 2015 Fitbit, The consumer tech company offers a familiar brand, profitability and explosive growth in the huge and fast growing wearables market
now a buy
no worries here
CYBR Secondary Filed, $50 Million Insiders Will Sell,Total Shares Not Decided.
CyberArk Files For Secondary Offering After Strong Q1
BY GILLIAN RICH, INVESTOR'S BUSINESS DAILY
6-8-15 08:54 AM ET
CyberArk Software (NASDAQ:CYBR) said Friday it filed for a follow-on stock offering.
The cybersecurity company filed a registration statement with the Securities and Exchange Commission for the secondary offering. The majority of the shares will be sold by current shareholders with $50 million in shares to be sold by CyberArk. The total number of shares to be sold hasn't been decided yet